Clinical Genomics Announces Appointment of Michael Dugan, M.D. as Chief Medical Officer

BRIDGEWATER, N.J., Nov. 14, 2016 (GLOBE NEWSWIRE) — Clinical Genomics, a private company developing evidence-driven diagnostic tools for colorectal cancer, today announced the appointment of Michael Dugan, M.D. as Chief Medical Officer. Dr. Dugan’s addition to the leadership team will strengthen the Company as it prepares to make Colvera™, a blood-based test for colorectal cancer (CRC) recurrence monitoring, available later this year.

“We are excited to welcome Dr. Dugan as CMO. His appointment comes at an important time as we approach the launch of Colvera,” said Lawrence LaPointe, Ph.D., President and CEO of Clinical Genomics. “Dr. Dugan’s extensive experience in developing and launching novel diagnostic tests make him uniquely suited to help us realize our near and long term goals. We are confident that his demonstrated track record across the entire product development continuum will bring value to our team.”

Dr. Dugan brings more than 20 years of executive-level experience in healthcare management, clinical development, market evaluation and laboratory operations to Clinical Genomics. Previously, he served as President and CEO of MCDXI Medical Diagnostics, where he led clinical evaluation, strategic development and clinical education efforts for several companies introducing novel diagnostic tests, platforms and related products to market.

Dr. Dugan’s previous roles include Senior Vice President of Clinical Development and Medical Affairs at Exact Sciences, Medical Director at Quest Diagnostics Nichols Institute and Vice President and Laboratory Director at Specialty Laboratories, Inc. He holds a B.S. in Biology from the University of Notre Dame, an M.D. from the University of Arizona College of Medicine, and completed postgraduate training in pathology and laboratory medicine at Yale University and UCLA.

About Colorectal Cancer (CRC)
Colorectal Cancer (CRC) is one of the leading causes of cancer-related deaths worldwide, accounting for more than 600,000 deaths each year. When diagnosed early, before cancer has spread, the relative five-year survival rate for CRC is 90 percent, but only approximately four out of 10 CRC cases are detected early. Among individuals undergoing surgical treatment for CRC, recurrence occurs in 30 to 40 percent of all cases, the majority of which present in the first two to three years following initial diagnosis and treatment.

About Clinical Genomics
Clinical Genomics is a privately held biotechnology company committed to reducing the impact of colorectal cancer (CRC) through early detection of disease and clinically actionable, evidence-driven recurrence monitoring tools. With a broad intellectual property portfolio consisting of more than 20 patents, Clinical Genomics, via its wholly-owned subsidiary Enterix Inc., currently offers the user-friendly, patient-preferred CRC screening InSure® FIT™ assay, a fecal immunochemical test that detects blood in the stool. InSure is also marketed as a lab-based test in Australia and other countries (ColoVantage Home). Building on an established history in the field of CRC screening and diagnosis, Clinical Genomics developed a sensitive and specific blood-based circulating tumor DNA (ctDNA) test for colorectal cancer based on methylated DNA from two genes, BCAT1 and IKZF1. The Company plans to offer this two-gene test for recurrence monitoring later in 2016.

Clinical Genomics has offices and laboratories in Bridgewater and Edison, New Jersey and Sydney, Australia, and operates as an FDA-registered and TGA-licensed manufacturer and a NATA-accredited laboratory.

For more information, please visit

CONTACT: Media Contact:
Danielle Lewis, Lazar Partners
(212) 843-0211 or (917) 907-4239